Ivonescimab, a PD-1/VEGFA bispecific antibody, is effective in advanced non-small cell lung cancer, but its efficacy in patients with baseline MPE and complex acquired resistance remains unclear. Here, VEGFA is linked to non-small cell lung carcinoma.